NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
4 trialsNCT02743221 2024-08-20
TASCO1
Servier
Phase 2 Completed
NCT04074343 2024-02-02
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
Phase 1 Completed
NCT04854434 2023-11-03
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Karyopharm Therapeutics Inc
Phase 2 Terminated